How to Sell a Hospice Agency in 2026

Hospice is still one of the highest-multiple subsectors in post-acute care M&A, but it's also the most scrutinized. Between the OIG's sustained focus on hospice eligibility, the rise of UPIC audits, the 2023 hospice Special Focus Program, and the ongoing mess in the four "hospice fraud hotspot" states (Arizona, California, Nevada, Texas), buyers are diligencing hospice deals like they diligence clinical trials. If you run a clean, ethically-operated agency with stable census, average length of stay in a defensible range, and low GIP utilization, you're in demand. If any of those are off, you're not selling at all.

The active PE-backed hospice platforms in 2026 include Compassus (TowerBrook and Ascension), Gentiva (Clayton Dubilier & Rice), Three Oaks Hospice (Webster Equity), Agape Care Group (Ridgemont Equity), St. Croix Hospice (H.I.G. Capital), Empassion, Traditions Health (Dorilton Capital), and BrightSpring's hospice segment. Strategic buyers include Amedisys (Optum) and Addus HomeCare. That's a real list of checkbooks — but they're all selective.

The 36-Month Rule Changes Everything

CMS's 36-month hospice ownership rule is the single most important thing to understand about selling a hospice agency. If the current owner acquired (or initially enrolled) the hospice within the last 36 months, a subsequent CHOW will trigger a requirement to re-enroll as a new hospice — meaning no Medicare billing under the existing CCN, a new CMS-855A, a new state survey, and potentially months of zero reimbursement.

The rule was explicitly designed to stop hospice flipping. It means that if you bought an agency in 2024, you generally cannot sell it (via CHOW) until 2027 without a punitive outcome. There are workarounds — equity sales of the parent entity, structural carveouts, sibling restructurings — but every one of them requires healthcare counsel with real hospice transaction experience. Firms like Polsinelli, Waller Lansden, Husch Blackwell, and Bass Berry & Sims are the ones buyers expect on the other side.

If you're outside the 36-month window and your compliance posture is clean, you have a much cleaner process. Confirm the enrollment history on your CMS-855A before you engage a banker.

Medicare Cap Exposure Is a Deal Killer

The aggregate Medicare hospice cap limits total payments per beneficiary over a cap year. For FY2026, the cap is in the neighborhood of $35,000 per beneficiary. Agencies that admit too many long-stay, non-cancer patients — or that skew heavily to dementia and debility diagnoses — can exceed the cap and owe CMS a retroactive repayment. Buyers will demand a cap calculation going back 5 years and will indemnify themselves against any undisclosed liability.

Pull your cap reports for every fiscal year and reconcile them to the MAC (Medicare Administrative Contractor) determination. Document any cap overages, the repayment status, and the corrective actions you took. Buyers will size an indemnification escrow — typically 10-15% of purchase price for 24-36 months — specifically against cap liability. Don't try to hide a cap exposure. The buyer's healthcare consultant (SimiTree, Fazzi, Cimarron, Weatherbee) will find it in week two of diligence.

Average length of stay (ALOS) is the other number buyers scrutinize. A well-run mixed-diagnosis hospice runs ALOS in the 75-95 day range. Over 110 days raises eligibility questions. Under 45 days suggests you're admitting too late and leaving revenue on the table. Your median length of stay should also be defensible — if your ALOS is 90 but your median is 12, you have a long-tail eligibility problem that buyers will not ignore.

GIP and Level of Care Mix

General Inpatient (GIP) level of care is the highest-paying hospice level and the most heavily audited. OIG has published multiple reports flagging inappropriate GIP billing, and UPICs target GIP claims disproportionately. Buyers underwrite GIP exposure on every deal.

The national GIP utilization rate is roughly 1-2% of total hospice days. Agencies running over 5% GIP without a clear clinical justification (high-acuity cancer program, inpatient unit with medical director oversight) are flagged immediately. If your GIP rate is elevated, get a clinical compliance review done before you bring the agency to market. Document the clinical rationale for each GIP admission — pain crisis, symptom management impossible at home, caregiver breakdown — and make sure your medical director notes support it.

Continuous home care (CHC) gets similar scrutiny. Low usage (under 0.5% of days) is normal. Consistent usage in the 2-3% range without clear clinical patterns draws auditor attention.

Survey History, Fraud Hotspots, and the Special Focus Program

Pull your last three state survey reports and any federal survey results. Document every condition-level deficiency, every standard-level citation, and every plan of correction. If you've had a condition-level finding in the last 24 months, buyers will want to see the full resolution and a follow-up survey with no repeat findings.

If your hospice operates in Arizona, California, Nevada, or Texas — the four states where CMS imposed the hospice enrollment moratorium and enhanced oversight — expect the buyer to apply a haircut or require additional compliance reps. Those markets have been flooded with bad actors, and legitimate operators are caught in the regulatory backlash. If you're a clean operator in those states, document it aggressively: ALOS, cap history, GIP rate, referral sources, survey history, and clinical outcomes.

The Hospice Special Focus Program, launched by CMS in 2024, identifies the lowest-performing 10% of hospices for enhanced oversight. Confirm your agency is not on the SFP list. If it is, you're not selling until you're off it.

What Buyers Pay For

Premium hospice multiples — still 10-13x EBITDA for quality mid-market assets in 2026 — go to agencies with these traits:

• ADC over 150 with a clear path to 200+. Sub-scale agencies (ADC under 75) trade at 5-7x if they trade at all.
• ALOS in the 75-95 day range with a defensible diagnosis mix (not dementia-heavy).
• Medicare cap headroom — current year utilization under 85% of cap.
• GIP under 3% with clear clinical documentation.
• Clean survey history — no condition-level findings in 24 months.
• Diversified referral base — no single hospital or SNF over 25% of admissions.
• Stable RN and chaplain staffing with turnover under 25% annually.

Running the Process

Hire a hospice specialist banker. Mertz Taggart, The Braff Group, Stoneridge Partners, Cain Brothers, and Provident all run hospice processes regularly and know the PE platforms actively deploying. Generalist bankers and business brokers do not understand the 36-month rule, the cap, or GIP dynamics well enough to position the deal correctly.

Invest in sell-side quality of earnings plus a hospice-specific compliance audit. Firms like SimiTree, Weatherbee Resources, and Fazzi Associates do pre-transaction hospice compliance reviews — chart samples, cap analysis, GIP audits, eligibility documentation review. The cost is $75-150K and it's the best insurance you can buy against a broken deal or a massive indemnification claim.

Expect 8-12 months from engagement to close. Deal structures include 15-20% escrow for 24-36 months, a separate cap indemnification holdback, and often a 1-2 year earnout tied to ADC, ALOS, and compliance metrics. Push back on any earnout tied to referral volume — you won't control it after close.

The Bottom Line

Hospice is still the highest-multiple home-based care subsector in 2026, but only for clean operators. Buyers have been burned by bad hospice deals and they are diligencing with lawyers, clinicians, and coders simultaneously. If you run a defensible agency outside the 36-month rule, with clean cap exposure, appropriate GIP utilization, and strong clinical documentation, there is real competition among PE-backed platforms. If any of those are problems, fix them first — or don't bother going to market.